Wuhan Binhui Biopharmaceutical Co., Ltd.
PrivateLast Round
Private Equity
Dec 1, 2023
Est. Valuation
$450M
Total Funding Raised
$159.8M
Company Overview
Wuhan Binhui Biopharmaceutical Co., Ltd. is a biotechnology company that specializes in the research, development, and production of oncolytic virus drugs and other macromolecular therapeutic products.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Wuhan Binhui Biopharmaceutical Co., Ltd. Comparables
Compare Wuhan Binhui Biopharmaceutical Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hangzhou ConVerd Co., Ltd. | 89% | |
| Beijing WellGene Biotech Co., Ltd. | 87% | |
| ImmVira | 85% |
Wuhan Binhui Biopharmaceutical Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Equity | Dec 1, 2023 | ||||
| Series B Extension | Apr 19, 2022 | ||||
| Series B | Feb 25, 2021 | ||||
| Series A | Aug 4, 2018 |
Wuhan Binhui Biopharmaceutical Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CCIC Capital | Series B |
| Haoyue Capital | Series B |
| Hubei High-tech Industrial Investment Group | Series B Extension |
| Qianhai Ark Asset Management | Series B |
| Share Capital | Series B |
| Ming Capital | Series B Extension |
| Vertex Ventures China | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 1, 2023
Raised $3M in a private equity round.
- Apr 19, 2022
$47M round led by Yangtze River Pharmaceutical Group
Wuhan Binhui Biopharmaceutical Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Wuhan Binhui Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.
Is Wuhan Binhui Biopharmaceutical Co., Ltd. a public or private company?
Wuhan Binhui Biopharmaceutical Co., Ltd. is a private company.
What is the current stock price of Wuhan Binhui Biopharmaceutical Co., Ltd.?
Wuhan Binhui Biopharmaceutical Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.
How much is Wuhan Binhui Biopharmaceutical Co., Ltd. worth (valuation)?
Wuhan Binhui Biopharmaceutical Co., Ltd.'s valuation is estimated at $450.0M based on funding round data.
Can I buy Wuhan Binhui Biopharmaceutical Co., Ltd. stock?
Wuhan Binhui Biopharmaceutical Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Wuhan Binhui Biopharmaceutical Co., Ltd.'s last funding round?
Wuhan Binhui Biopharmaceutical Co., Ltd.'s most recent funding round was Private Equity on December 1, 2023.
Who are the main investors in Wuhan Binhui Biopharmaceutical Co., Ltd.?
Key investors in Wuhan Binhui Biopharmaceutical Co., Ltd. include CCIC Capital, Qianhai Ark Asset Management, Share Capital, Vertex Ventures China.
Will Wuhan Binhui Biopharmaceutical Co., Ltd. IPO soon?
No public IPO plans have been announced for Wuhan Binhui Biopharmaceutical Co., Ltd..
How can I track Wuhan Binhui Biopharmaceutical Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Wuhan Binhui Biopharmaceutical Co., Ltd.'s secondary market activity and sign up for updates.